303 related articles for article (PubMed ID: 36098029)
1. Characterising frailty, metrics of continuous glucose monitoring, and mortality hazards in older adults with type 2 diabetes on insulin therapy (HARE): a prospective, observational cohort study.
Fung E; Lui LT; Huang L; Cheng KF; Lau GHW; Chung YT; Ahmadabadi BN; Xie S; Lee JSW; Hui E; So WY; Sung JJY; King I; Goggins WB; Chan Q; Järvelin MR; Ma RCW; Chow E; Kwok T
Lancet Healthy Longev; 2021 Nov; 2(11):e724-e735. PubMed ID: 36098029
[TBL] [Abstract][Full Text] [Related]
2. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
Krajnc M; Kravos Tramšek NA
Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
[TBL] [Abstract][Full Text] [Related]
3. Glucose profiles of older adults with type 1 diabetes using sensor-augmented pump therapy in Australia: pre-randomisation results from the ORACL study.
Trawley S; Ward GM; Vogrin S; Colman PG; Fourlanos S; Grills CA; Lee MH; MacIsaac RJ; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; McAuley SA
Lancet Healthy Longev; 2022 Dec; 3(12):e839-e848. PubMed ID: 36410370
[TBL] [Abstract][Full Text] [Related]
4. The effects of aging and frailty on inpatient glycemic control by continuous glucose monitoring in patients with type 2 diabetes.
Idrees T; Zabala ZE; Moreno EM; Gerges A; Urrutia MA; Ruiz JG; Vaughan C; Vellanki P; Pasquel FJ; Peng L; Umpierrez GE
Diabetes Res Clin Pract; 2023 Apr; 198():110603. PubMed ID: 36871877
[TBL] [Abstract][Full Text] [Related]
5. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T
Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954
[TBL] [Abstract][Full Text] [Related]
6. Glucose Targets Using Continuous Glucose Monitoring Metrics in Older Adults With Diabetes: Are We There Yet?
Toschi E; O'Neal D; Munshi M; Jenkins A
J Diabetes Sci Technol; 2024 Jul; 18(4):808-818. PubMed ID: 38715259
[TBL] [Abstract][Full Text] [Related]
7. Relationship of continuous glucose monitoring-related metrics with HbA1c and residual β-cell function in Japanese patients with type 1 diabetes.
Babaya N; Noso S; Hiromine Y; Taketomo Y; Niwano F; Yoshida S; Yasutake S; Kawabata Y; Ikegami H
Sci Rep; 2021 Feb; 11(1):4006. PubMed ID: 33597626
[TBL] [Abstract][Full Text] [Related]
8. Daytime Glycemic Variability and Frailty in Older Patients with Diabetes: a Pilot Study Using Continuous Glucose Monitoring.
Chung SM; Lee YH; Kim CO; Lee JY; Jin SM; Yoo SH; Moon JS; Kim KJ
J Korean Med Sci; 2021 Jul; 36(27):e190. PubMed ID: 34254474
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
Matsuda E; Brennan P
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-10. PubMed ID: 27820140
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes.
Irace C; Cutruzzolà A; Nuzzi A; Assaloni R; Brunato B; Pitocco D; Tartaglione L; Di Molfetta S; Cignarelli A; Laviola L; Citro G; Lovati E; Gnasso A; Tweden KS; Kaufman FR
Diabetes Obes Metab; 2020 Jul; 22(7):1056-1061. PubMed ID: 32037699
[TBL] [Abstract][Full Text] [Related]
11. Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy.
Rodbard D
Diabetes Obes Metab; 2023 Feb; 25(2):596-601. PubMed ID: 36314133
[TBL] [Abstract][Full Text] [Related]
12. Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: A post-hoc analysis of the GlucoMOMS trial.
Rademaker D; van der Wel AWT; van Eekelen R; Voormolen DN; de Valk HW; Evers IM; Mol BW; Franx A; Siegelaar SE; van Rijn BB; DeVries JH; Painter RC;
Diabetes Obes Metab; 2023 Dec; 25(12):3798-3806. PubMed ID: 37735847
[TBL] [Abstract][Full Text] [Related]
13. Reduction of clinically important low glucose excursions with a long-term implantable continuous glucose monitoring system in adults with type 1 diabetes prone to hypoglycaemia: the France Adoption Randomized Clinical Trial.
Renard E; Riveline JP; Hanaire H; Guerci B;
Diabetes Obes Metab; 2022 May; 24(5):859-867. PubMed ID: 34984786
[TBL] [Abstract][Full Text] [Related]
14. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
[TBL] [Abstract][Full Text] [Related]
15. Relationship between key continuous glucose monitoring-derived metrics and specific cognitive domains in patients with type 2 diabetes mellitus.
Dong S; Wang L; Zhao C; Zhang R; Gao Z; Jiang L; Guo Y; Zhou H; Xu S
BMC Neurol; 2023 May; 23(1):200. PubMed ID: 37210479
[TBL] [Abstract][Full Text] [Related]
16. Individualization of recommendations from the international consensus on continuous glucose monitoring-derived metrics in Japanese children and adolescents with type 1 diabetes.
Urakami T; Yoshida K; Kuwabara R; Mine Y; Aoki M; Suzuki J; Morioka I
Endocr J; 2020 Oct; 67(10):1055-1062. PubMed ID: 32565500
[TBL] [Abstract][Full Text] [Related]
17. The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control.
Yoshii H; Mita T; Katakami N; Okada Y; Osonoi T; Aso K; Kurozumi A; Wakasugi S; Sato F; Ishii R; Gosho M; Shimomura I; Watada H
J Clin Endocrinol Metab; 2022 Sep; 107(10):e3990-e4003. PubMed ID: 35908248
[TBL] [Abstract][Full Text] [Related]
18. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement.
Battelino T; Alexander CM; Amiel SA; Arreaza-Rubin G; Beck RW; Bergenstal RM; Buckingham BA; Carroll J; Ceriello A; Chow E; Choudhary P; Close K; Danne T; Dutta S; Gabbay R; Garg S; Heverly J; Hirsch IB; Kader T; Kenney J; Kovatchev B; Laffel L; Maahs D; Mathieu C; Mauricio D; Nimri R; Nishimura R; Scharf M; Del Prato S; Renard E; Rosenstock J; Saboo B; Ueki K; Umpierrez GE; Weinzimer SA; Phillip M
Lancet Diabetes Endocrinol; 2023 Jan; 11(1):42-57. PubMed ID: 36493795
[TBL] [Abstract][Full Text] [Related]
19. Time-in-Range With Insulin Versus Metformin in Gestational Diabetes Mellitus Using Continuous Glucose Monitoring: A Randomized Control Study at a Tertiary Care Centre in South India.
Pandey A; Tejerao Naik B; Uday R; Channabasappa S
Cureus; 2024 Jun; 16(6):e61849. PubMed ID: 38855483
[TBL] [Abstract][Full Text] [Related]
20. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials.
Maiorino MI; Signoriello S; Maio A; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Giugliano D; Esposito K
Diabetes Care; 2020 May; 43(5):1146-1156. PubMed ID: 32312858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
